Combination therapy using aspirin-enhanced photodynamic selective drug delivery

Vascular Pharmacology

Volumn 46, Issue 3, 2007, Pages 171-180

  Debefve, E ^a   Pegaz, B ^a   Ballini, J P ^a   Konan, Y N ^a   van den Bergh, H ^a  

^a EPFL   (Switzerland)

Author keywords

Age related macular degeneration (AMD); Cancer; Chorioallantoic membrane (CAM); Drug delivery; Leakage; Photodynamic therapy (PDT)

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; BENZOPORPHYRIN DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; CANCER CHEMOTHERAPY; CHICK EMBRYO; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; HEMOSTASIS; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSTIMULATION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

ANIMALS; ASPIRIN; BLOOD VESSELS; CHICK EMBRYO; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DRUG DELIVERY SYSTEMS; FLUORESCEIN ANGIOGRAPHY; HEPARIN; MACULAR DEGENERATION; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 33846257713     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2006.09.006     Document Type: Article

References (34)

1. D'Amico D.J., et al. Anecortave Acetate as Monotherapy for the Treatment of Subfoveal Lesions in Patients with Exudative Age-related Macular Degeneration (AMD): Interim (Month 6) Analysis of Clinical Safety and Efficacy. Retina 23 1 (2003) 14-23
2. Costa R.A., et al. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 23 2 (2003) 159-165
3. Fingar V.H. Vascular effects of photodynamic therapy. J. Clin. Laser Med. Surg. 14 5 (1996) 323-328
4. Fingar V., et al. The role of microvascular damage in photodynamic therapy - the effect of treatment on vessel constriction, permeability and leucocyte adhesion. Cancer Res. 52 18 (1992) 4914-4921
5. Fingar V.H., Wieman T.J., and Haydon P.S. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem. Photobiol. 66 4 (1997) 513-517
6. Fingar V.H., et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer 79 11-12 (1999) 1702-1708
7. Gottfried V., et al. In vivo damage to chorioallantoic membrane blood vessels by porphycene-induced photodynamic therapy. J. Photochem. Photobiol., B Biol. 30 2-3 (1995) 115-121
8. Hammer-Wilson M.J., et al. Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for topically applied photosensitizers. J. Photochem. Photobiol., B Biol. 53 1-3 (1999) 44-52
9. Hornung R., et al. Systemic application of photosensitizers in the chick chorioallantoic membrane (CAM) model: photodynamic response of CAM vessels and 5-aminolevulinic acid uptake kinetics by transplantable tumors. J. Photochem. Photobiol., B Biol. 49 1 (1999) 41-49
10. Janka H.U. Inhibition of platelet adenylate-cyclase by aspirin - a further argument for a low-dose regimen in anti-platelet drug-therapy. IRCS Med. Sci., Biochem. 9 11 (1981) 1019-1019
11. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res. 21 6B (2001) 4271-4277
12. Krzystolik M.G., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120 3 (2002) 338-346
13. Lange N., et al. A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Investig. Ophthalmol. Vis. Sci. 42 1 (2001) 38-46
14. Michels S., and Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Investig. Ophthalmol. Vis. Sci. 44 5 (2003) 2147-2154
15. Miller J.W., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch. Ophthalmol. 117 9 (1999) 1161-1173
16. Morant J., and Ruppaner H. Compendium Suisse des Médicaments (2002), Documed SA, Basel, Switzerland
17. Mori K., et al. Angiography by scanning laser ophthalmoscope with fluorescein compounds of different physicochemical properties. Nippon Ganka Gakkai Zasshi 101 4 (1997) 318-326
18. Novacek G., et al. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. Thromb. Res. 88 3 (1997) 283-290
19. Reed M.W., Schuschke D.A., and Miller F.N. Prostanoid antagonists inhibit the response of the microcirculation to ''early'' photodynamic therapy. Radiat. Res. 127 3 (1991) 292-296
20. Romanoff A.L. Biochemistry of the Avian Embryo: a Quantitative Analysis of Prenetal Development (1967), John Wiley and Sons, New York 398
21. Rosenblum W., and El-Sabban F. Platelet-aggregation in cerebral microcirculation-effect of aspirin and other agents. Circ. Res. 40 3 (1977) 320-328
22. Schmidt-Erfurth U., et al. Time course and morphology of vascular effects associated with photodynamic therapy. Ophtalmology 112 12 (2005) 2061-2069
23. Sharman W.M., Allen C.M., and van Lier J.E. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov. Today 4 11 (1999) 507-517
24. Snyder J.W., et al. Photodynamic therapy: a means to enhanced drug delivery to tumors. Cancer Res. 63 23 (2003) 8126-8131
25. Sporn L.A., and Foster T.H. Photofrin and light induces microtubule depolymerization in cultured human endothelial cells. Cancer Res. 52 12 (1992) 3443-3448
26. Stern S.J., et al. Effect of aspirin on photodynamic therapy utilizing chloroaluminum sulfonated phthalocyanine (CASP). Lasers Surg. Med. 12 5 (1992) 494-499
27. Taber S.W., Wieman T.J., and Fingar V.H. The effects of aspirin on microvasculature after photodynamic therapy. Photochem. Photobiol. 57 5 (1993) 856-861
28. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. One year results of 2 randomized clinical trials. TAP report 1. Arch. Ophthalmol. 117 10 (1999) 1329-1345
29. TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch. Ophthalmol. 119 (2001) 198-207
30. TAP Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. three-year results of an open-label extension of 2 randomized clinical trials - TAP report 5. Arch. Ophthalmol. 120 10 (2002) 1307-1314
31. TAP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch. Ophthalmol. 120 11 (2002) 1443-1454
32. TAP Study Group. Effects of verteporfin therapy on contrast on sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No 4. Retina 22 5 (2002) 536-544
33. van den Bergh H. Photodynamic therapy of age-related macular degeneration: history and principles. Seminars in Ophthalmology 16 4 (2001) 181-200
34. Yamamoto Y., et al. Fibrin plugging as a cause of microcirculatory occlusion during photodynamic therapy. Lasers Med. Sci. 14 2 (1999) 129-135